August 6, 2025 — Leads & Copy — Evotec SE (Frankfurt Stock Exchange:EVT, MDAX/TecDAX, Prime Standard, ISIN: DE0005664809, WKN 566480; NASDAQ:EVO) will release its half-year interim report for the first six months of 2025 on Wednesday, August 13, 2025. The Company will host a conference call in English to discuss the results and provide a performance update.
The webcast is scheduled for Wednesday, August 13, 2025, at 2:00 pm CEST (1:00 pm BST, 8:00 am EDT). Registration for the audio webcast and presentation slides is available via this link. An on-demand version will be available on Evotec’s website.
To join the conference call via phone, pre-register via this link to receive dial-in details.
Evotec is a life science company focused on drug discovery and development, integrating science with AI-driven innovation and technologies. The company’s expertise includes small molecules, biologics, and cell therapies, supported by platforms like Molecular Patient Databases and iPSC-based disease modeling. Evotec partners with Top 20 Pharma companies, biotechs, academic institutions, and healthcare stakeholders.
Evotec has a global team of over 4,800 experts operating from sites in Europe and the U.S.
Volker Braun, EVP Head of Global Investor Relations & ESG, Volker.Braun@evotec.com
Source: Evotec SE
